CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Clinical trial NCT06231368 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06231368
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Autoimmune Hemolytic Anemia Autologous CD19 CAR-T Failure of Three or More Lines of Therapy

Start date: 2024-02-04
Primary completion: 2024-11-18
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.